13.03.2017 – 07:10

AEVIS VICTORIA SA

EQS-Adhoc: AEVIS VICTORIA SA: Stellungnahme zum Bericht des Verwaltungsrats der LifeWatch AG

EQS Group-Ad-hoc: AEVIS VICTORIA SA / Schlagwort(e): Übernahmeangebot
AEVIS VICTORIA SA: Stellungnahme zum Bericht des Verwaltungsrats der LifeWatch
AG

13.03.2017 / 07:05 CET/CEST
Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR
--------------------------------------------------------------------------------
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND
JAPAN

Pressemitteilung

Freiburg, 13. März 2017

AEVIS VICTORIA: Stellungnahme zum Bericht des Verwaltungsrats der LifeWatch AG

AEVIS VICTORIA SA (AEVIS VICTORIA) hat vom Bericht des Verwaltungsrats der
LifeWatch AG (LifeWatch) zum öffentlichen Kaufangebot der AEVIS VICTORIA
Kenntnis genommen. Sie bedauert, dass der dafür gebildete Ausschuss das
freundliche Angebot der AEVIS VICTORIA zur Ablehnung empfiehlt. Noch vor einem
Jahr hatte der Verwaltungsrat den Einstieg eines potentiellen Ankeraktionärs
explizit begrüsst und die Zusammensetzung des Gremiums entsprechend verändert.

AEVIS VICTORIA stellt zudem fest, dass der Verwaltungsrat von LifeWatch keine
präzisen Zahlen zur Untermauerung seiner Empfehlung, das Angebot abzulehnen,
vorlegte und dass er für die Beurteilung des Angebots kein unabhängiges
Bewertungsgutachten (Fairness Opinion) in Auftrag gegeben hat. Im Rahmen des
Angebots  von AEVIS VICTORIA wurde Ernst & Young beauftragt, ein unabhängiges
Bewertungsgutachten über die AEVIS VICTORIA-Aktie zu erstellen. Die Analyse von
Ernst & Young bewertet das Tauschangebot für die LifeWatch-Aktionäre zwischen
CHF 12.40 bis CHF 13.60 pro LifeWatch-Aktie.

AEVIS VICTORIA ist davon überzeugt, dass LifeWatch einen starken Ankeraktionär
mit breiter Präsenz im Gesundheitssektor braucht, der eine langfristige Vision
mitbringt und die erforderlichen finanziellen Mittel zur Weiterentwicklung des
Geschäftsmodells einbringen kann.

Nach erfolgreichem Abschluss des Angebots würde LifeWatch als eigenständig
geführte Tochtergesellschaft in die AEVIS VICTORIA-Gruppe integriert werden. Die
Telemedizin-Aktivitäten von AEVIS VICTORIA würden damit nachhaltig gestärkt.

Bezug der Angebotsunterlagen:
Der Angebotsprospekt kann bei UBS AG, Prospectus Library, Postfach, 8098 Zürich,
Tel. +41 44 239 47 03, Fax +41 44 239 69 14, Email  swiss-prospectus@ubs.com
bestellt werden.

Die Dokumentation kann ebenfalls über den nachstehenden Link bezogen werden:
http://www.aevis.com/websites/aevis/German/3700/uebrige-informationen.html

Für weitere Informationen:
AEVIS VICTORIA SA Medienstelle und Investor Relations: c/o Dynamics Group,
Zurich
Philippe R. Blangey,  prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 oder +41 (0) 79
785 46 32
Séverine Van der Schueren,  svanderschueren@aevis.com, +41 (0) 26 350 02 02

AEVIS VICTORIA SA - Investing for a better life
AEVIS VICTORIA SA investiert im Healthcare-Bereich, in Life Sciences sowie in
die medizinische Betreuung und in Lifestyle-Dienstleistungen. Die Beteiligungen
von AEVIS VICTORIA bestehen aus der zweitgrössten Privatklinikgruppe der
Schweiz, Swiss Medical Network, aus Victoria-Jungfrau Collection, einer
Luxushotelgruppe bestehend aus fünf Häusern, aus der Swiss Healthcare Properties
AG, eine auf Gesundheitsimmobilien fokussierte Gesellschaft, aus Medgate, dem
führenden Telemedizinanbieter in der Schweiz und aus NESCENS SA, einer Marke
rund um das Thema better-aging. AEVIS VICTORIA ist an der SIX Swiss Exchange im
Swiss Reporting Standard unter dem Kürzel AEVS.SW kotiert (www.aevis.com).


RESTRICTIONS TO THE OFFER

General
The offer described in this press release is not made directly or indirectly in
any country or jurisdiction in which such offer would be considered unlawful or
in which it would otherwise violate any applicable law or regulation, or which
would require the offeror to amend the terms or conditions of the offer in any
way, or which would require the offeror to make any additional filing with or
take any additional action with regard to any governmental, regulatory or legal
authority. The offeror does not intend to extend the offer to any such country
or jurisdiction. Documents relating to the offer may not be distributed in such
countries or jurisdictions or sent into such countries or jurisdictions and may
not be used for purposes of soliciting the purchase of any securities of
LifeWatch by any person or entity resident or incorporated in such countries or
jurisdictions.

United States of America
The public tender offer described in this press release is not made directly or
indirectly in or by use of the mail of, or by any means or instrumentality of
interstate or foreign commerce of, or any facilities of a national securities
exchange of, the United States of America and may only be accepted outside the
United States of America. This includes, but is not limited to, facsimile
transmission, telex or telephones. This press release and any offering materials
with respect to the public tender offer described in this press release may not
be distributed in nor sent to the United States of America and may not be used
for the purpose of soliciting the sale or purchase of any securities of
LifeWatch from anyone in the United States of America. The offeror will not be
soliciting the tender of securities of LifeWatch by any holder of such
securities in the United States of America. Securities of LifeWatch will not be
accepted from holders of such securities in the United States of America. Any
purported acceptance of the offer that the offeror or its agents believe has
been made in or from the United States of America will be invalidated. The
offeror reserves the absolute right to reject any and all acceptances determined
by them not to be in the proper form or the acceptance of which may be unlawful.

The securities to be issued pursuant to the public tender offer described in
this press release have not been and will not be registered under the U.S.
Securities Act of 1933, as amended (the "U.S. Securities Act"), nor under any
law of any state of the United States of America, and may not be offered, sold,
resold, or delivered, directly or indirectly, in or into the United States of
America, except pursuant to an exemption from the registration requirements of
the U.S. Securities Act and the applicable state securities laws. Neither this
press release nor the public tender offer described in this press release does
constitute an offer to sell or the solicitation of an offer to buy any
securities in the United States of America or in any other jurisdiction in which
such an offer or solicitation would be unlawful. Securities may not be offered
or sold in the United States of America absent registration or an exemption from
registration. AEVIS will not register or make a public offer of its securities,
or otherwise conduct the public tender offer, in the United States of America.

United Kingdom
This communication is directed only at persons in the U.K. who (i) have
professional experience in matters relating to investments, (ii) are persons
falling within article 49(2)(a) to (d) ("high net worth companies,
unincorporated associations, etc") of The Financial Services and Markets Act
2000 (Financial Promotion) Order 2005 or (iii) to whom it may otherwise lawfully
be communicated (all such persons together being referred to as "relevant
persons"). This communication must not be acted on or relied on by persons who
are not relevant persons. Any investment or investment activity to which this
communication relates is available only to relevant persons and will be engaged
in only with relevant persons.

Australia, Canada, Japan
The public tender offer described in this press release is not addressed to
shareholders of LifeWatch whose place of residence, seat or habitual abode is in
Australia, Canada or Japan, and such shareholders may not accept the offer.

European Economic Area
The public tender offer described in this press release (the "Offer") is only
being made within the European Economic Area ("EEA") pursuant to an exemption
under Directive 2003/71/EC (as amended and together with any applicable adopting
or amending measures in any relevant member state (as defined below), the
"Prospectus Directive"), as implemented in each member state of the EEA (each a
"relevant member state"), from the requirement to publish a prospectus that has
been approved by the competent authority in that relevant member state and
published in accordance with the Prospectus Directive as implemented in that
relevant member state or, where appropriate, approved in another relevant member
state and notified to the competent authority in that relevant member state, all
in accordance with the Prospectus Directive. Accordingly, in the EEA, the Offer
and documents or other materials in relation to the offer and the shares in
AEVIS (the "Offeror Shares") are only addressed to, and are only directed at,
(i) qualified investors ("qualified investors") in the relevant member state
within the meaning of Article 2(1)(e) of the Prospectus Directive, as adopted in
the relevant member state, and (ii) persons who hold, and will tender, the
equivalent of at least EUR 100,000 worth of shares in LifeWatch (the "Target
Shares") in exchange for the receipt of offeror Shares (collectively, "permitted
participants"). This press release and the documents and other materials in
relation to the offer may not be acted or relied upon by persons in the EEA who
are not permitted participants, and each shareholder of LifeWatch seeking to
participate in the offer that is resident in the EEA will be deemed to have
represented and agreed that it is a qualified investor or that it is tendering
the equivalent of EUR 100,000 worth of Target Shares in exchange of offeror
Shares.

--------------------------------------------------------------------------------
Ende der Ad-hoc-Mitteilung------------------------------------------------------

553201  13.03.2017 CET/CEST